<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04263987</url>
  </required_header>
  <id_info>
    <org_study_id>MOLEP Study</org_study_id>
    <nct_id>NCT04263987</nct_id>
  </id_info>
  <brief_title>A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial</brief_title>
  <official_title>A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Holmium laser enucleation of the prostate (HOLEP) has proven to be efficacious and safe for&#xD;
      the treatment of benign prostatic hypertrophy (BPH). New laser technologies such as the Moses&#xD;
      Pulse laser system provide for improved energy delivery which may decrease blood loss and&#xD;
      operative time. We seek to evaluate Moses technology for enucleation of the prostate in the&#xD;
      setting of BPH.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, prospective, double-blinded, randomized controlled trial comparing&#xD;
      MOLEP to HOLEP. Inclusion criteria included all symptomatic BPH patients desiring enucleation&#xD;
      with prostate sizes &gt; 80ccs based on cross-sectional imaging. Patients are randomized in a&#xD;
      1:1 fashion and the study is powered to evaluate for a difference in operative time (i.e.&#xD;
      alpha=0.05,N=21 per group). All surgeries will be performed with a 550 Î¼m fiber. At the start&#xD;
      of each case, a laser technician would be notified of randomization via envelope and&#xD;
      randomize the settings to either Moses or traditional mode. The surgeons and patients were&#xD;
      blinded to which mode was used. All surgeries will be performed using a two lobe technique&#xD;
      and laser settings between 2J and 20-40Hz. Further recorded endpoints include change in blood&#xD;
      loss, reduction in International Prostate Symptom Score (IPSS), improvement in uroflow&#xD;
      parameters, and complications postoperatively at 6 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Actual">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Operative time</measure>
    <time_frame>intraoperatively</time_frame>
    <description>time for surgery to take place</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood loss</measure>
    <time_frame>postoperatively day 1</time_frame>
    <description>Change in hematocrit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Holmium Laser Enucleation of Prostate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Traditional holmium laser enucleation of the prostate as currently performed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moses Holmium Laser Enucleation of Prostate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>holmium laser enucleation of the prostate as currently performed but with Moses laser settings activated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Moses laser enucleation of prostate</intervention_name>
    <description>Using the moses settings with the Lumenis laser system to evaluate outcomes for enucleation of the prostate; hypothesis is that it leads to faster operative time</description>
    <arm_group_label>Holmium Laser Enucleation of Prostate</arm_group_label>
    <arm_group_label>Moses Holmium Laser Enucleation of Prostate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any man with clinical symptoms fo BPH requiring surgery who has a prostate sized at&#xD;
             greater than 80 grams&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anyone actively on anticoagulation perioperatively&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>For prostatic disease</gender_description>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 7, 2020</study_first_submitted>
  <study_first_submitted_qc>February 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2020</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Nicholas Kavoussi</investigator_full_name>
    <investigator_title>Clinical Instructor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

